What's Happening?
Astellas Pharma has decided to terminate its collaboration with CytomX Therapeutics, a partnership that was focused on developing masked bispecific antibody therapies for solid tumors. This decision comes despite CytomX reporting positive early data for its Probody
platform, which is designed to target cancer cells more effectively while minimizing damage to healthy tissues. The partnership, initiated in March 2020, involved Astellas paying $80 million upfront to utilize CytomX's technology for multiple cancer programs. Under the agreement, CytomX was responsible for early research, while Astellas was to handle preclinical and clinical development, as well as regulatory and commercialization activities. CytomX's Probody technology uses a masking approach to limit antibody activity until they reach the tumor microenvironment, thereby reducing potential side effects. Despite the termination, CytomX continues to advance its lead asset, varsetatug masetecan, which has shown a 32% confirmed response rate in a Phase 1 study for metastatic colorectal cancer.
Why It's Important?
The termination of the partnership between Astellas and CytomX highlights the challenges and uncertainties in the pharmaceutical industry, particularly in the development of innovative cancer therapies. While CytomX's Probody platform has shown promising results, the decision by Astellas to withdraw could impact the pace and scope of future developments. This move may also influence investor confidence and strategic decisions within the biotech sector, as partnerships are crucial for sharing risks and resources in drug development. For CytomX, the end of this collaboration means a potential loss of significant milestone payments and royalties, which could affect its financial stability and ability to fund ongoing research. However, the company retains other partnerships with major players like Regeneron and Moderna, which may help mitigate the impact.
What's Next?
CytomX plans to continue the development of its Probody platform independently and is prioritizing further studies of varsetatug masetecan. The company has initiated additional trials, including a combination study with Roche's Avastin, and plans to start a Phase 1b/2 trial with Avastin and chemotherapy by the end of the year. These efforts aim to validate the efficacy and safety of their approach in treating colorectal cancer. The outcome of these trials will be crucial for CytomX's future, potentially attracting new partnerships or investment opportunities. Meanwhile, Astellas may seek other collaborations or focus on different therapeutic areas to advance its oncology pipeline.
